Fabrazyme 35 mg, poudre pour solution à diluer pour perfusion - Durchstechflasche(n) Swissmedic Key 56261002 Registration Holder Sanofi-Aventis (Suisse) SA Name Fabrazyme 35 mg, poudre pour solution à diluer pour perfusion Date of registration 25.07.2003 Introduction of Sequence 25.07.2003 ATC-Classification Agalsidase Beta (A16AB04) Revision date 23.11.2004 WHO WHO-DDD Valid until Index Therapeuticus (BSV) 07.14. Show package size Durchstechflasche(n) Index Therapeuticus (Swissmedic) 07.14. Description Swissmedic categorie. A SL Eintrag Yes Indication Information for professionals IP Consumer information CI Ex-factory-Price 3348.27 Limitation No Deductible 10 % Consumer price 3657.85 Feedback FB GTIN 7680562610027 Medication Code Biotechnologika Pharmacode 2842878 Disponibility
Composition Praeparatio cryodesiccata: agalsidasum beta 35 mg, mannitolum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, pro vitro, natrium 12.83 mg. Packungsbestandteile Label Praeparatio cryodesiccata:
Galenic Form poudre pour solution à diluer pour perfusion Excipiens Active Agent Dose Agalsidase Beta 35 mg
BAG: Active Agent Dose Agalsidase Beta 35 mg
Inactive agents Disodium Phosphate Heptahydrate Mannitol Sodium Dihydrogenophosphate Monohydrate
Source Data was imported : 04.07.2024
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
